The design of new combinatorial regimens represents an opportunity to improve response to immune checkpoint inhibitors in patients with cancer. Here the authors computationally model the interaction between chemotherapy and immunotherapy by studying treatment-induced expression changes associated with response to anti-PD-1, identifying chemotherapeutic drugs or small molecule inhibitors that can overcome resistance to anti-PD-1.
- Yue Wang
- Dhamotharan Pattarayan
- Da Yang
